+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Japan
Publications
News & Events
Careers
Contact
Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
Home
Publications
Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
Back Home
Cost-effectiveness of oxaliplatin/5FU/LV (FOLFOX) vs. irinotecan/5FU/LV (IFL) as first-line treatment of metastatic colorectal cancer
2006
Aballea, S. | Najib, M. | Cure, S. | O'Neil, B. |
Volume: 17, Issue: vi66, Pages: ,
colon cancer, cost-effectiveness analysis, poster,
